. The reduction in the oxygenation status caused by hydralazine is insufficient for detection by 31P-NMR in human xenografted tumours, whereas in RIF-1, SCCVII/Ha and KHT murine tumours large increases in the Pi/total phosphate ratio are found (Bremner et al., 1991; Adams et al., 1992) . In the light of these discrepancies, a number of relevant issues need to be clarified regarding the relationship between energy status and tumour blood flow. In the present study, the key questions were as follows:
There is an increasing body of experimental evidence available suggesting that 'chronic' decreases in tumour blood flow and/or tissue oxygenation during tumour growth or acute declines in the tissue perfusion upon therapeutic measures are accompanied by a significant energy deprivation. Strong positive correlations between energy status and tumour perfusion or tissue oxygenation have been described for several murine tumour systems (e.g. Lilly et al., 1985; Evelhoch et al., 1986; Tozer et al., 1987; Vaupel et al., 1989a, b; Steen & Graham, 1991) . These investigations led to the conclusion that blood flow may ultimately determine the bioenergetic status of tumours during growth. Any studies investigating changes in the energy status in tumours induced by physical, chemical or biological manoeuvres should thus be cognisant of alterations in blood flow. Changes in tumour blood flow following vasodilators Tozer et al., 1990) , high-dose hyperthermia (Sijens et al., 1987; Kruger et al., 1991; Mayer et al., 1992) , tumour necrosis factor a (TNF-a), lymphotoxin or interleukin 1 (Constantinidis et al., 1989; Kluge et al., 1992) , X-irradiation (Tozer et al., 1989) or after i.p. mannitol administration are always followed by parallel alterations in tumour energy status. The only exception to this rule seems to be the constant energy status found after i.p. or i.v. glucose administration when stable or even transiently improved energy status is observed Kruger et al., 1991; Mayer et al., 1992; Schaefer et al., 1993) .
Under conditions in which blood flow through a tumour is substantially reduced, hyperglycaemia (and (Bremner et al., 1993) . The reduction in the oxygenation status caused by hydralazine is insufficient for detection by 31P-NMR in human xenografted tumours, whereas in RIF-1, SCCVII/Ha and KHT murine tumours large increases in the Pi/total phosphate ratio are found (Bremner et al., 1991; Adams et al., 1992) . In the light of these discrepancies, a number of relevant issues need to be clarified regarding the relationship between energy status and tumour blood flow. In the present study, the key questions were as follows:
(1) Do Amersham-Buchler, Braunschweig, Germany) was applied as a bolus injection through the arterial catheter into the thoracic aorta. The registration of the washout process was performed with a Geiger-counting tube con-nected to a ratemeter (FHT 1100 FAG Kugelfischer, Erlangen, Germany). The method of evaluation of TBF was identical to that described earlier (Kluge et al., 1992) . Measurements were performed on tumours of varying sizes at 20 min intervals before application of TNF-x and at 30 min intervals thereafter over a total time period of 2 h post treatment. In all experiments performed in this study, animals were allowed to stabilise following the surgical procedures. Measurements commenced once constant baseline readings for MABP and flow were obtained for at least 20 min.
Laser Dopplerflowmetry A Periflux model PF 3 dual-channel laser Doppler flowmeter was used for this study (2 mW He-Ne laser, wavelength 632.8 nm; Perimed, Stockholm, Sweden). Laser Doppler flow (LDF) signals were continuously recorded from central locations on the tumour surface using a type PF 108 probe. The fibreoptic probe was placed above (but not in contact with) the tumour tissue under study. LDF was recorded for 10 min before i.v. administration of TNF-o or saline (control) and for 90 min thereafter (Kluge et al., 1992) .
Tumour oxygen tension measurements Tumour oxygen tension values were determined using polarographic needle electrodes (recessed 12 lam gold in glass cathode; shaft diameter 250 pLm) and P02 histography (model KIMOC-6650, Eppendorf, Hamburg, Germany) as described previously . Measurements were made either on tumours of varying sizes or before and 120 min after acute flow changes upon TNF-a application.
Measurement ofglobal concentrations of adenylate phosphates in perchloric acid extracts In order to obtain mean (global) levels of adenylate phosphates, the tumour-bearing hindfoot was rapidly frozen and the tumours (n = 12) were prepared under liquid nitrogen and stored at -80°C for further processing. In a first series of experiments, tumours of varying sizes were analysed. In another series, tumours were assayed before or 120 min after administration of TNF-o.
Each deep-frozen tumour was ground to a fine powder and freeze dried. For determination of ATP, ADP and AMP levels, aliquots of freeze-dried tissue were extracted with 0.66 M perchloric acid, centrifuged and the supernatant neutralised with 2 M potassium hydroxide. The concentrations of the adenylate phosphates were then determined using reversed-phase high-performance liquid chromatography (HPLC) techniques at 254 nm (for more details see Kruger et al., 1991; Schaefer et al., 1993) . Concentrations were expressed as j.mol per g tissue wet weight.
Determination of microregional A TP distribution Before preparing the rapidly frozen tumours for HPLC analysis, approximately 30% of the tumour mass was separated, cut at -25°C in a cryostat into 5-nm sections and used for ATP bioluminescence measurements to assess the microregional ATP distribution using single-photon imaging and quantitative bioluminescence (for methodological details see Walenta et al., 1992; Schaefer et al., 1993) . The spatial resolution gained by this method is about 50 jam, thus revealing information about the intra-tumour variability of the ATP levels in relation to histological details.
Introduction of acuteflow drops through TNF-c
Recombinant human TNF-x (specific activity: 8.2 x 106 U per mg of protein; Knoll, Ludwigshafen, Germany) was diluted in isotonic phosphate-buffered saline solution containing 0.5% (w/w) bovine serum albumin (Sigma Chemie, Deisenhofen, Germany). TNF-ao was given into the external jugular vein at a dose level of 1 mg kg-' over approximately 3 min. The catheter used for the i.v. route was flushed with saline thereafter. Control animals received identical fluid loads (1 ml kg-' phosphate-buffered saline i.v.). For further details see Kluge et al. (1992) .
Statistical analysis
Results are expressed as means ± s.e. with the numbers of experiments indicated in brackets. Significance was assessed using the paired or unpaired Student's t-test, as appropriate. Results were considered as significant if P-values were less than 5% (P<0.05).
Results and Discussion
Like many other experimental tumour systems, tumour blood flow (TBF) and tissue oxygenation significantly decrease in the DS sarcoma with increasing tumour mass (see Figure 1 ).
Starting from a mean TBF value of 0.98 ml g-1 min-' in the smallest tumours investigated, flow decreased by about 50% in the larger malignancies (2P<0.001). This flow drop coincides with a similar decrease in the mean Po2 value from 39 to 16mmHg (2P<0.001).
As long as tumour masses do not exceed 1% of the body weight (i.e. biologically relevant tumour sizes), global ATP concentrations and adenylate energy charge remain almost constant. During tumour growth from 0.86 ± 0.02 to 2.15 ± 0.04 g, ATP concentrations insignificantly increased from 1.15 ± 0.10 to 1.37 ± 0.12 jtmol g-'. Similar results were obtained when the microregional ATP distribution was analysed in three tissue sections of three tumours each of three different size groups (mean tumour weights: 0.82±0.08g, 1.25±0.10g and 2.14±0.12g; see Figure   1 ).
Flow and P02 values in these tumour size ranges are similar to those observed in many normal tissues (Vaupel et al., 1989c) and are seen to be accompanied by a stable energy status. Changes in TBF can influence tissue oxygenation but not ATP concentrations in this tissue. This may be explained by an intensified glycolytic rate as the oxygenation status deteriorates and/or a decreasing number of proliferating cells which compensate for the poorer oxygen supply as the tumours become larger. As long as TBF and/or P02 values do not fall below a certain 'threshold', tumour energy status can be maintained. Under these conditions, glucose has to be considered as the major energy source, which is available in sufficient amounts even under normoglycaemic conditions. roximately 50% (v/v); Gullino et al., 1965; Vaupel & MiillerKlieser, 1983; Stubbs et al., 1992] , the mean tissue glucose concentration is > 1.5 gmol g-1 ('reservoir function' of the interstitial space). The missing decrease in high-energy phosphates despite severe restrictions in tumour blood flow during hyperglycaemia as observed in rodent tumours supports this notion Kruger et al., 1991; Schaefer et al., 1993) . In line with these findings is a recent study of Gerweck et al. (1993) showing that energy status and oxygenation are not closely linked in the presence of glucose. Similar observations have been described for other experimental tumour systems. In an amelanotic hamster melanoma (A-Mel-3), ATP concentrations remained constant as long as blood flow values were above 0.4 ml g' min-' (Walenta et al., 1992) . This finding is based on pixel-to-pixel correlations between microregional ATP concentrations and flow data.
In murine FSaII tumours, median P02 values of 10-15 mmHg represent a critical threshold for energy metabolism . At higher median P02 values, ATP levels were relatively constant. On average, median oxygen tensions below 10-15 mmHg coincided with ATP depletion, intracellular acidosis, a drop in the energy charge and rising Pi levels (Vaupel, 1992) . These conditions were, however, only found when tumour masses were > 1.5% of body weight.
Stable bioenergetic status is observed not only during 'growth-related' decreases in blood flow or tissue P02 values, but also upon acute falls in TBF following TNF-a administration. This cytokine is known to drastically reduce microcirculatory function (Kluge et al., 1992; Naredi et al., 1993) .
Starting from TBF values of 0.98 ± 0.05 ml g-' min-' (tumour wet weights: 0.85 ± 0.05 g), TNF-x application resulted in a 50% flow drop within 120 min (Figure 2 ). Similar changes were observed for the tumour P02 distribution. Despite these substantial changes, ATP levels, phosphocreatine (PCr)/Pi and P-nucleoside triphosphate (I3-NTP)/Pi ratios remained almost unchanged*.
Here again, energy status was stable at mean flow values 0.5 ml g-'min-1, mean oxygen tensions > 13 mmHg and mean tumour tissue glucose levels > 1.4 iLmol g-' (Engel & Vaupel, 1993) . From the data presented it is concluded that growth-related or acute changes in tumour perfusion are, as a rule, accompanied by parallel alterations of tissue oxygena-*PCr/Pi and NTP/Pi ratios were obtained from 31P-NMR spectroscopy (Kluge et al., 1992) 
